Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Continuing Operations (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Income from Continuing Operations for 16 consecutive years, with 3825000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 117.04% to 3825000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 15071000.0 through Dec 2025, up 394.64% year-over-year, with the annual reading at 15071000.0 for FY2025, 394.64% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 3825000.0 at Gyre Therapeutics, down from 5936000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 51632000.0 in Q2 2022, with the low at 100977000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 8001650.0, with a median of 2216000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations plummeted 453.2% in 2021, then soared 359.42% in 2022.
  • Over 5 years, Income from Continuing Operations stood at 20387000.0 in 2021, then plummeted by 41.21% to 28788000.0 in 2022, then crashed by 250.76% to 100977000.0 in 2023, then surged by 77.77% to 22444000.0 in 2024, then skyrocketed by 117.04% to 3825000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 3825000.0, 5936000.0, and 1576000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.